Journal Article
. 2006 Jun;17(8).
doi: 10.1093/annonc/mdl135.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

M Martín 1 A Lluch  M A Seguí  A Ruiz  M Ramos  E Adrover  A Rodríguez-Lescure  R Grosse  L Calvo  C Fernandez-Chacón  M Roset  A Antón  D Isla  P Martínez del Prado  L Iglesias  J Zaluski  A Arcusa  J M López-Vega  M Muñoz  J R Mel  
Affiliations
  • PMID: 16766587
  •     58 citations

Abstract

Background: The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, cyclophosphamide) with and without primary prophylactic G-CSF (PPG).

Patients And Methods: This was a phase III study to compare FAC and TAC as adjuvant treatment of high-risk node-negative breast cancer patients. After the entry of the first 237 patients, the protocol was amended to include PPG in the TAC arm due to the high incidence of febrile neutropenia. A total of 1047 evaluable patients from 49 centres in Spain, two in Poland and four in Germany were included in the trial. Side-effects and the scores of the EORTC QLQ-C30 and QLQ BR-23 questionnaires were compared in the three groups (FAC, TAC pre-amendment and TAC post-amendment).

Results: The addition of PPG to TAC significantly reduced the incidence of neutropenic fever, grade 2-4 anaemia, asthenia, anorexia, nail disorders, stomatitis, myalgia and dysgeusia. Patient QoL decreased during chemotherapy, more with TAC than FAC, but returned to baseline values afterwards. The addition of PPG to TAC significantly reduced the percentage of patients with clinically relevant Global Health Status deterioration (10 or more points over baseline value) at the end of chemotherapy (64% versus 46%, P<0.03).

Conclusions: The addition of PPG significantly reduces the incidence of neutropenic fever associated with TAC chemotherapy as well as that of some TAC-induced haematological and extrahaematological side-effects. The HRQoL of patients treated with TAC is worse than that of those treated with FAC but improves with the addition of PPG, particularly in the final part of chemotherapy treatment.

Canadian supportive care recommendations for the management of neutropenia in patients with cancer.
C T Kouroukis, S Chia, +4 authors, J Mikhael.
Curr Oncol, 2008 Mar 05; 15(1). PMID: 18317581    Free PMC article.
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.
Ruth Pettengell, Matthias Schwenkglenks, +6 authors, Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU).
Support Care Cancer, 2008 Mar 21; 16(11). PMID: 18351398
Delayed emotional recovery after taxane-based chemotherapy.
Lisa M Thornton, William E Carson, +2 authors, Barbara L Andersen.
Cancer, 2008 Jun 04; 113(3). PMID: 18521922    Free PMC article.
Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.
Ali Montazeri.
J Exp Clin Cancer Res, 2008 Sep 02; 27. PMID: 18759983    Free PMC article.
Highly Cited. Review.
Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.
M Martín-Jiménez, A Rodríguez-Lescure, +2 authors, M Brosa-Riestra.
Clin Transl Oncol, 2009 Jan 22; 11(1). PMID: 19155203
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
Alfredo Carrato, Luis Paz-Ares Rodríguez, +13 authors, Spanish Society of Medical Oncology (SEOM).
Clin Transl Oncol, 2009 Jul 04; 11(7). PMID: 19574202
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
Review.
Supportive care for patients with early breast cancer.
Laura García-Estévez, Ignasi Tusquets, +5 authors, Ana Lluch.
Clin Transl Oncol, 2010 Jan 19; 12(1). PMID: 20080469
Review.
Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.
N Mittmann, S Verma, +2 authors, M Trudeau.
Curr Oncol, 2010 Feb 25; 17(1). PMID: 20179798    Free PMC article.
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Matti Aapro, Jeffrey Crawford, Didier Kamioner.
Support Care Cancer, 2010 Mar 02; 18(5). PMID: 20191292    Free PMC article.
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
Alexandre Chan, Wing Hang Fu, +3 authors, Raymond Ng.
Support Care Cancer, 2010 Mar 17; 19(4). PMID: 20232087
Current controversies in the management of breast cancer.
I Tusquets, L García-Estévez, +17 authors, A Lluch.
Clin Transl Oncol, 2010 May 14; 12(4). PMID: 20462837
Review.
A systematic review of dysgeusia induced by cancer therapies.
Allan J Hovan, P Michele Williams, +6 authors, Dysgeusia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO).
Support Care Cancer, 2010 May 25; 18(8). PMID: 20495984
Systematic Review.
The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.
Rupert Bartsch, Guenther G Steger.
Breast Care (Basel), 2009 Jan 01; 4(3). PMID: 20847876    Free PMC article.
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
Laetitia Gerlier, Mark Lamotte, +11 authors, Luc Somers.
BMC Cancer, 2010 Nov 26; 10. PMID: 21092320    Free PMC article.
Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.
Orit Freedman, Eitan Amir, Camilla Zimmermann, Mark Clemons.
Support Care Cancer, 2011 Jan 05; 19(3). PMID: 21203780
Systematic Review.
Heath-related quality of life in Spanish breast cancer patients: a systematic review.
María Concepción Delgado-Sanz, María José García-Mendizábal, +4 authors, Beatriz Pérez-Gómez.
Health Qual Life Outcomes, 2011 Jan 18; 9. PMID: 21235770    Free PMC article.
Systematic Review.
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.
D E Peterson, R-J Bensadoun, F Roila, ESMO Guidelines Working Group.
Ann Oncol, 2011 Oct 20; 22 Suppl 6. PMID: 21908510    Free PMC article.
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Robert I Griffiths, Richard L Barron, +5 authors, Gary H Lyman.
Pharmacoeconomics, 2011 Oct 05; 30(2). PMID: 21967155
Refining docetaxel-containing therapy for gastric cancer.
Nushmia Z Khokhar, Yixing Jiang, +2 authors, Mary F Mulcahy.
Gastrointest Cancer Res, 2011 Nov 02; 4(3). PMID: 22043325    Free PMC article.
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Jocelyne Jacquemier, Jean-Marie Boher, +12 authors, François Bertucci.
Breast Cancer Res, 2011 Nov 03; 13(6). PMID: 22044691    Free PMC article.
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Tallal Younis, Daniel Rayson, Kara Thompson.
Support Care Cancer, 2012 Jan 19; 20(10). PMID: 22252548
Systematic Review.
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model.
Christian Franci, Jenny Zhou, +4 authors, Hosein Kouros-Mehr.
PLoS One, 2013 Mar 23; 8(3). PMID: 23520493    Free PMC article.
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Heather-Jane Au, Wolfgang Eiermann, +18 authors, Translational Research in Oncology BCIRG 006 Trial Investigators.
Oncologist, 2013 Jul 03; 18(7). PMID: 23814044    Free PMC article.
Evaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of Lentinula edodes mycelia extract.
Yukiko Nagashima, Noriko Maeda, +2 authors, Masaaki Oka.
Onco Targets Ther, 2013 Jul 23; 6. PMID: 23874107    Free PMC article.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Alexandra Schönherr, Viktoria Aivazova-Fuchs, +14 authors, Brigitte Rack.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904831    Free PMC article.
Improving symptom communication through personal digital assistants: the CHAT (Communicating Health Assisted by Technology) project.
Douglas M Post, Charles L Shapiro, +8 authors, Electra D Paskett.
J Natl Cancer Inst Monogr, 2014 Jan 08; 2013(47). PMID: 24395985    Free PMC article.
Weight change and its impact on prognosis after adjuvant TAC (docetaxel-doxorubicin-cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer.
Ye Won Jeon, Seung Taek Lim, Hyun Joo Choi, Young Jin Suh.
Med Oncol, 2014 Feb 06; 31(3). PMID: 24496561
Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.
J A Pérez-Fidalgo, B Bermejo, +7 authors, A Lluch.
Clin Transl Oncol, 2014 Feb 18; 16(9). PMID: 24532305    Free PMC article.
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Wendy J Langeberg, Conchitina C Siozon, +2 authors, Victoria M Chia.
Support Care Cancer, 2014 Mar 22; 22(8). PMID: 24652049
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment.
Alessandro Marco Minisini, Jessica Menis, +2 authors, Gianpiero Fasola.
Clin Pract, 2011 May 16; 1(2). PMID: 24765295    Free PMC article.
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Review.
Myelo-enhancement by astragalus membranaceus in male albino rats with chemotherapy myelo-suppression. Histological and immunohistochemical study.
Zeinab Mohamed Kamel Ismail, Noha Mohamed Afifi Amin, Mira Farouk Youssef Yacoub, Amira Mohamed Osman Mohamed.
Int J Stem Cells, 2014 Jun 13; 7(1). PMID: 24921023    Free PMC article.
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
E Hall, D Cameron, +6 authors, TACT Trial Investigators.
Eur J Cancer, 2014 Jul 30; 50(14). PMID: 25065293    Free PMC article.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Yoshimasa Kosaka, Yoshiaki Rai, +7 authors, Kazuo Tamura.
Support Care Cancer, 2015 Jan 13; 23(4). PMID: 25576433    Free PMC article.
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.
Norikazu Masuda, Yutaka Tokuda, +3 authors, Kazuo Tamura.
Support Care Cancer, 2015 Mar 04; 23(10). PMID: 25733000    Free PMC article.
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Wei Zhang, Zhiwei Jiang, +2 authors, Jielai Xia.
Med Oncol, 2015 Mar 31; 32(5). PMID: 25820754
Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.
Jennifer Eremin, Ged Cowley, +3 authors, Oleg Eremin.
Springerplus, 2015 May 23; 4. PMID: 25995984    Free PMC article.
The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.
Eva Culakova, Marek S Poniewierski, +3 authors, Gary H Lyman.
Springerplus, 2015 Aug 08; 4. PMID: 26251780    Free PMC article.
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Ki Hyeong Lee, Ji-Yeon Kim, +15 authors, Seock-Ah Im.
Support Care Cancer, 2015 Oct 02; 24(4). PMID: 26423618    Free PMC article.
Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.
Ilhan Hacibekiroglu, Hilmi Kodaz, +5 authors, Irfan Cicin.
Mol Clin Oncol, 2015 Dec 02; 3(5). PMID: 26623070    Free PMC article.
Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.
Rui-Min Ma, Chuan-Zhi Chen, +3 authors, Gui-Long Guo.
Medicine (Baltimore), 2016 Apr 05; 95(13). PMID: 27043697    Free PMC article.
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
K H Park, S Lee, +11 authors, Jae Hong Seo.
Support Care Cancer, 2016 Oct 07; 25(2). PMID: 27709313
Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Qiu-Wen Tan, Ting Luo, +5 authors, Qing Lv.
Chin J Cancer, 2017 Mar 09; 36(1). PMID: 28270181    Free PMC article.
Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.
Romina Sosa, Shuling Li, +3 authors, Allan J Collins.
Support Care Cancer, 2017 May 01; 25(10). PMID: 28456908
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.
Jyoti Bajpai, Deepa Susan, +4 authors, Sudeep Gupta.
Indian J Med Paediatr Oncol, 2017 May 05; 38(1). PMID: 28469332    Free PMC article.
Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan.
M J Fischer, K Inoue, +13 authors, A A Kaptein.
Breast Cancer Res Treat, 2017 Aug 02; 166(2). PMID: 28762012    Free PMC article.
Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement.
Yukiko Nagashima, Shigehumi Yoshino, +9 authors, Nagano Hiroaki.
Mol Clin Oncol, 2017 Aug 16; 7(3). PMID: 28811898    Free PMC article.
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.
A Krendyukov, M Schiestl, N Höbel, M Aapro.
Support Care Cancer, 2017 Sep 21; 26(1). PMID: 28929372    Free PMC article.
Review.
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Isabel Puértolas, Alberto Frutos Pérez-Surio, +2 authors, María Del Tránsito Salvador.
Eur J Clin Pharmacol, 2017 Nov 21; 74(3). PMID: 29152672
Taxanes for adjuvant treatment of early breast cancer.
Melina L Willson, Lucinda Burke, +3 authors, Nicholas Wilcken.
Cochrane Database Syst Rev, 2019 Sep 03; 9. PMID: 31476253    Free PMC article.
Systematic Review.
Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Helen V Worthington, Jan E Clarkson, +6 authors, Tasneem Khalid.
Cochrane Database Syst Rev, 2011 Apr 15; (4). PMID: 21491378    Free PMC article.
Systematic Review.
A systematic review of utility values for chemotherapy-related adverse events.
Fatiha H Shabaruddin, Li-Chia Chen, Rachel A Elliott, Katherine Payne.
Pharmacoeconomics, 2013 Mar 27; 31(4). PMID: 23529208
Systematic Review.
Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis.
Xiang Li, Huan Zheng, +4 authors, Juan Xu.
Support Care Cancer, 2020 Jul 06; 28(11). PMID: 32621264    Free PMC article.
Systematic Review.
Life Quality Index Assessment in Breast Cancer Patients.
Sanjiv Srivastava, Alpana Srivastava, Sandeep Tiwari, Anand K Mishra.
Indian J Surg Oncol, 2019 Sep 10; 10(3). PMID: 31496595    Free PMC article.
Review.
Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer.
Muhammad Adeel, Muhammad Asif, +3 authors, Muhammad Khalid.
Cancer Manag Res, 2019 Jan 31; 11. PMID: 30697066    Free PMC article.
The Impact of AC and AC-T Chemotherapy's Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study.
Diriba Alemayehu Gadisa, Shu-Hua Wang, Getnet Yimer.
Breast Cancer (Dove Med Press), 2021 Mar 05; 13. PMID: 33658844    Free PMC article.